全文获取类型
| 收费全文 | 1599551篇 |
| 免费 | 133552篇 |
| 国内免费 | 2577篇 |
专业分类
| 耳鼻咽喉 | 21646篇 |
| 儿科学 | 52928篇 |
| 妇产科学 | 46225篇 |
| 基础医学 | 227761篇 |
| 口腔科学 | 47196篇 |
| 临床医学 | 140898篇 |
| 内科学 | 314755篇 |
| 皮肤病学 | 34090篇 |
| 神经病学 | 130098篇 |
| 特种医学 | 64721篇 |
| 外国民族医学 | 474篇 |
| 外科学 | 243790篇 |
| 综合类 | 39712篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 544篇 |
| 预防医学 | 122856篇 |
| 眼科学 | 36470篇 |
| 药学 | 121250篇 |
| 3篇 | |
| 中国医学 | 2974篇 |
| 肿瘤学 | 87286篇 |
出版年
| 2018年 | 14763篇 |
| 2016年 | 12898篇 |
| 2015年 | 15025篇 |
| 2014年 | 20645篇 |
| 2013年 | 31349篇 |
| 2012年 | 42545篇 |
| 2011年 | 44748篇 |
| 2010年 | 26335篇 |
| 2009年 | 25302篇 |
| 2008年 | 42995篇 |
| 2007年 | 45237篇 |
| 2006年 | 46047篇 |
| 2005年 | 44671篇 |
| 2004年 | 44088篇 |
| 2003年 | 42177篇 |
| 2002年 | 41289篇 |
| 2001年 | 75682篇 |
| 2000年 | 78326篇 |
| 1999年 | 66387篇 |
| 1998年 | 17731篇 |
| 1997年 | 16334篇 |
| 1996年 | 16314篇 |
| 1995年 | 16019篇 |
| 1994年 | 15070篇 |
| 1993年 | 14217篇 |
| 1992年 | 55427篇 |
| 1991年 | 53775篇 |
| 1990年 | 52561篇 |
| 1989年 | 50832篇 |
| 1988年 | 47221篇 |
| 1987年 | 46560篇 |
| 1986年 | 44284篇 |
| 1985年 | 42843篇 |
| 1984年 | 32033篇 |
| 1983年 | 27565篇 |
| 1982年 | 16144篇 |
| 1981年 | 14436篇 |
| 1980年 | 13564篇 |
| 1979年 | 30460篇 |
| 1978年 | 21064篇 |
| 1977年 | 17764篇 |
| 1976年 | 16694篇 |
| 1975年 | 17574篇 |
| 1974年 | 21486篇 |
| 1973年 | 20672篇 |
| 1972年 | 18853篇 |
| 1971年 | 17770篇 |
| 1970年 | 16289篇 |
| 1969年 | 15268篇 |
| 1968年 | 13949篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
201.
Miguel A. Sanz Pau Montesinos Haesook T. Kim Guillermo J. Ruiz-Argüelles María S. Undurraga María R. Uriarte Lem Martínez Rafael H. Jacomo Homero Gutiérrez-Aguirre Raul A. M. Melo Rosane Bittencourt Ricardo Pasquini Katia Pagnano Evandro M. Fagundes Edo Vellenga Alexandra Holowiecka Ana J. González-Huerta Pascual Fernández Javier De la Serna Salut Brunet Elena De Lisa José González-Campos José M. Ribera Isabel Krsnik Arnold Ganser Nancy Berliner Raul C. Ribeiro Francesco Lo-Coco Bob L?wenberg Eduardo M. Rego 《Annals of hematology》2015,94(8):1347-1356
202.
203.
Daniel J. Snyder Thomas R. Kroshus Aakash Keswani Evan B. Garden Karl M. Koenig Kevin J. Bozic David S. Jevsevar Jashvant Poeran Calin S. Moucha 《The Journal of arthroplasty》2019,34(4):613-618
Background
Nursing Home Compare (NHC) ratings, created and maintained by Medicare, are used by both hospitals and consumers to aid in the skilled nursing facility (SNF) selection process. To date, no studies have linked NHC ratings to actual episode-based outcomes. The purpose of this study was to evaluate whether NHC ratings are valid predictors of 90-day complications, readmission, and bundle costs for patients discharged to an SNF after primary total joint arthroplasty (TJA).Methods
All SNF-discharged primary TJA cases in 2017 at a multihospital academic health system were queried. Demographic, psychosocial, and clinical variables were manually extracted from the health record. Medicare NHC ratings were then collected for each SNF. For patients in the Medicare bundle, postacute and total bundle cost was extracted from claims.Results
Four hundred eighty-eight patients were discharged to a total of 105 unique SNFs. In multivariate analysis, overall NHC rating was not predictive of 90-day readmission/major complications, >75th percentile postacute cost, or 90-day bundle cost exceeding the target price. SNF health inspection and quality measure ratings were also not predictive of 90-day readmission/major complications or bundle performance. A higher SNF staffing rating was independently associated with a decreased odds for >75th percentile 90-day postacute spend (odds ratio, 0.58; P = .01) and a 90-day bundle cost exceeding the target price (odds ratio = 0.69; P = .02) but was similarly not predictive of 90-day readmission/complications.Conclusion
Results of our study suggest that Medicare's NHC tool is not a useful predictor of 90-day costs, complications, or readmissions for SNFs within our health system. 相似文献204.
Bimal Bhindi Christine M. Lohse Phillip J. Schulte Ross J. Mason John C. Cheville Stephen A. Boorjian Bradley C. Leibovich R. Houston Thompson 《European urology》2019,75(5):766-772
Background
Partial nephrectomy (PN) is generally favored for cT1 tumors over radical nephrectomy (RN) when technically feasible. However, it can be unclear whether the additional risks of PN are worth the magnitude of renal function benefit.Objective
To develop preoperative tools to predict long-term estimated glomerular filtration rate (eGFR) beyond 30 d following PN and RN, separately.Design, setting, and participants
In this retrospective cohort study, patients who underwent RN or PN for a single nonmetastatic renal tumor between 1997 and 2014 at our institution were identified. Exclusion criteria were venous tumor thrombus and preoperative eGFR <15 ml/min/1.73 m2.Intervention
RN and PN.Outcome measurements and statistical analysis
Hierarchical generalized linear mixed-effect models with backward selection of candidate preoperative features were used to predict long-term eGFR following RN and PN, separately. Predictive ability was summarized using marginal , which ranges from 0 to 1, with higher values indicating increased predictive ability.Results and limitations
The analysis included 1152 patients (13 206 eGFR observations) who underwent RN and 1920 patients (18 652 eGFR observations) who underwent PN, with mean preoperative eGFRs of 66 ml/min/1.73 m2 (standard deviation [SD] = 18) and 72 ml/min/1.73 m2 (SD = 20), respectively. The model to predict eGFR after RN included age, diabetes, preoperative eGFR, preoperative proteinuria, tumor size, time from surgery, and an interaction between time from surgery and age (marginal ). The model to predict eGFR after PN included age, presence of a solitary kidney, diabetes, hypertension, preoperative eGFR, preoperative proteinuria, surgical approach, time from surgery, and interaction terms between time from surgery and age, diabetes, preoperative eGFR, and preoperative proteinuria (marginal ). Limitations include the lack of data on renal tumor complexity and the single-center design; generalizability needs to be confirmed in external cohorts.Conclusions
We developed preoperative tools to predict renal function outcomes following RN and PN. Pending validation, these tools should be helpful for patient counseling and clinical decision-making.Patient summary
We developed models to predict kidney function outcomes after partial and radical nephrectomy based on preoperative features. This should help clinicians during patient counseling and decision-making in the management of kidney tumors. 相似文献205.
Die Unfallchirurgie - Zur Diagnostik von Schultergelenkerkrankungen wird routinemäßig die Magnetresonanztomographie (MRT) durchgeführt. Diese kann entsprechend der klinischen... 相似文献
206.
207.
208.
209.
210.
A.B. Sanchez-Spitman J.J. Swen V.O. Dezentje D.J.A.R. Moes H. Gelderblom 《Expert review of clinical pharmacology》2019,12(6):523-536
Introduction: Tamoxifen dominates the anti-estrogenic therapy in the early and metastatic breast cancer setting. Tamoxifen has a complex metabolism, being mainly metabolized by CYP2D6 into its 30–100 times more potent metabolite, endoxifen. Recently, a phase I study in which endoxifen as an orally z-endoxifen hydrochloride has been successfully evaluated.
Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献